These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2686426)

  • 21. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
    Nix DE; Cumbo TJ; Kuritzky P; DeVito JM; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):146-53. PubMed ID: 3555029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
    Lesse AJ; Freer C; Salata RA; Francis JB; Scheld WM
    Am J Med; 1987 Apr; 82(4A):247-53. PubMed ID: 3555043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections.
    Haddow A; Greene S; Heinz G; Wantuck D
    Am J Med; 1989 Nov; 87(5A):113S-115S. PubMed ID: 2686410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections.
    Ramirez-Ronda CH; Saavedra S; Rivera-Vázquez CR
    Am J Med; 1987 Apr; 82(4A):220-3. PubMed ID: 3555040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
    Bouza E; Díaz-López MD; Bernaldo de Quirós JC; Rodríguez-Créixems M
    Am J Med; 1989 Nov; 87(5A):228S-231S. PubMed ID: 2589366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.
    Paladino JA; Sperry HE; Backes JM; Gelber JA; Serrianne DJ; Cumbo TJ; Schentag JJ
    Am J Med; 1991 Nov; 91(5):462-70. PubMed ID: 1951408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral ciprofloxacin in resistant urinary tract infections.
    Ryan JL; Berenson CS; Greco TP; Mangi RJ; Sims M; Thornton GF; Andriole VT
    Am J Med; 1987 Apr; 82(4A):303-6. PubMed ID: 3555052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
    Lorian V; Pavletich K
    Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
    Parish LC; Asper R
    Am J Med; 1987 Apr; 82(4A):227-9. PubMed ID: 3555041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous ciprofloxacin for the treatment of severe infections.
    Santini C; Baiocchi P; Venditti M; Gelfusa V; Tarasi A; Brandimarte C; Serra P
    J Chemother; 1991 Apr; 3(2):121-5. PubMed ID: 1875231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections.
    Kljucar S; Heimesaat M; von Pritzbuer E; Timm J; Scholl H; Beermann D
    Am J Med; 1989 Nov; 87(5A):52S-56S. PubMed ID: 2589385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure.
    Gentry LO; Koshdel A
    Am J Med; 1989 Nov; 87(5A):132S-135S. PubMed ID: 2686413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
    Davis C
    Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
    Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
    BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
    Brown AE; Smith G
    Am J Med; 1989 Nov; 87(5A):266S-268S. PubMed ID: 2589376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections.
    Pankey GA
    Clin Ther; 1995; 17(3):353-65. PubMed ID: 7585840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
    Fass RJ
    Am J Med; 1987 Apr; 82(4A):202-7. PubMed ID: 3555037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.